Monocyte Proliferation via Cytokine Culture Medium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing dendritic cell vaccines are inefficient and burdensome, requiring multiple apheresis sessions and struggling to achieve sufficient cell numbers due to low monocyte proliferation rates, which can lead to prolonged treatment times and patient discomfort.
Innovation Solution
A method involving the use of a cytokine-rich culture medium containing GM-CSF, IFN-γ, and Flt-3L to efficiently proliferate monocytes in vitro, allowing for the production of sufficient dendritic cells without the need for repeated cell cultures and reducing patient burden.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional apheresis method is used to collect monocytes, then monocytes can be obtained, but the apparatus is expensive and requires advanced skills to operate
Solution Approach 1:
The patent replaces expensive, complex apheresis apparatus with simple, disposable materials including centrifuge tubes, culture plates, and standard laboratory equipment. The method uses conventional centrifugation and culture techniques that require minimal specialized equipment, making the process accessible to ordinary laboratories without expensive apheresis machines.
Solution Approach 2:
The patent divides the monocyte collection process into separate, manageable steps: blood collection by simple venipuncture, centrifugation to separate mononuclear cells, and culture to enrich monocytes. This segmentation allows each step to be performed with simple, standard equipment rather than requiring a single complex apheresis apparatus.
2Quantity of substance
If conventional apheresis method is used to collect monocytes, then monocytes can be obtained, but multiple apheresis sessions are required to achieve sufficient cell numbers
Solution Approach 1:
The patent performs preliminary monocyte enrichment through in vitro culture before vaccine production begins. By culturing monocytes for 3-7 days with appropriate cytokines (GM-CSF, M-CSF, or GM-CSF plus IL-4), the method pre-concentrates monocytes from the initial blood sample, eliminating the need for repeated apheresis sessions to accumulate sufficient cell numbers.
Solution Approach 2:
The patent establishes continuous monocyte proliferation through culture conditions that maintain high monocyte viability and promote division. The use of cytokine-containing culture media creates a continuous growth environment, allowing monocytes to multiply over several days rather than requiring discrete, repeated collection sessions.
3Quantity of substance
If conventional culture method is used to differentiate monocytes into dendritic cells, then differentiation can occur, but sufficient cell numbers cannot be obtained
Solution Approach 1:
The patent optimizes culture parameters including cytokine concentrations (GM-CSF at 100-500 ng/mL, M-CSF at 100-500 ng/mL, or GM-CSF plus IL-4), culture duration (3-7 days for monocyte enrichment followed by differentiation), and cell density to maximize both monocyte proliferation and subsequent dendritic cell differentiation efficiency, achieving sufficient cell numbers for vaccine production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the rapid and efficient production of a sufficient number of dendritic cells for vaccine production, reducing treatment time and minimizing patient discomfort while maintaining high cell viability and antigen-presenting ability.
Implementation Method 1
a method involving the use of a cytokine-rich culture medium containing GM-CSF, IFN-γ, and Flt-3L to efficiently proliferate monocytes in vitro
Data Source
Figure 1A~1B
Figure 2
Figure 3A~3C
AI summary
The purpose of the present invention is to provide a means for proliferating a monocyte with high efficiency and in a simple manner. The present invention provides a proliferating agent for a monocyte, which consists of at least one component selected from Flt-3L, IL-3 and IFN-γ and can be used before a treatment for differentiation of a monocyte into a dendritic cell. The present invention also provides a culture medium for use in the proliferation of a monocyte, which contains at least one component selected from Flt-3L, IL-3 and IFN-γ and can be used before a treatment for differentiation of a monocyte into a dendritic cell. The culture medium for use in the proliferation of a monocyte according to the present invention may contain GM-CSF.